Bone Marrow Transplant. 2010 Aug 9; Hematopoietic SCT for the treatment of multiple sclerosis. Atkins H Abstract Multiple sclerosis (MS) is the leading autoimmune indication for autologous hematopoietic SCT (aHSCT). Patient selection criteria and transplant interventions have been refined through a series of cohort and registry studies. High- and low-intensity chemotherapy-based conditioning regimens have been…

Adv Exp Med Biol. 2010;671:41-57 Stem cell transplantation methods. Tran KD, Ho A, Jandial R Abstract Just a few short years ago, we still used to think that we were born with a finite number of irreplaceable neurons. However, in recent years, there has been increasingly persuasive evidence that suggests that neural stem cell (NSC)…

2010 Aug; 16(8) : 909-18 Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mallam E, Kemp K, Wilkins A, Rice C, Scolding N Abstract Recent studies have investigated the potential of autologous bone marrow-derived mesenchymal stem cells (MSCs) as a therapy for multiple sclerosis. Whether MSCs from individuals…

2010 Jul 27;224(1-2):101-7 Cell replacement therapies to promote remyelination in a viral model of demyelination. Tirotta E, Carbajal KS, Schaumburg CS, Whitman L, Lane TE Abstract Persistent infection of the central nervous system (CNS) of mice with the neuroadapted JHM strain of mouse hepatitis (MHV) is characterized by ongoing demyelination mediated by inflammatory T cells…

2010 Jun; 23(3) : 218-25 Stem cell transplantation in multiple sclerosis. Uccelli A, Mancardi G Abstract The recent advances in our understanding of stem cell biology, the availability of innovative techniques that allow large-scale acquisition of stem cells, and the increasing pressure from the multiple sclerosis (MS) patient community seeking tissue repair strategies have launched…

2010 Jun;16(6):685-93 High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Krasulovã¡ E, Trneny M, Kozã¡k T, Vackovã¡ B, Pohlreich D, Kemlink D, Kobylka P, Kovã¡rovã¡ I, Lhotã¡kovã¡ P, Havrdovã¡ E Abstract There are multiple sclerosis patients who suffer from an aggressive course of the disease with…

Cent Nerv Syst Agents Med Chem. 2010 Mar; 10(1) : 3-15 Multiple sclerosis – established and novel therapeutic approaches. Ehling R, Berger T, Reindl M Abstract Multiple sclerosis (MS) is the most common disabling neurological disease in young adults characterized by recurrent relapses and / or progression that are attributable to multifocal inflammation, demyelination and…

2010 May;6(3):347-52 Hematopoietic stem cell transplantation in multiple sclerosis: a review of the clinical experience and a report of an international meeting. Karussis D, Vaknin-Dembinsky A Abstract Hematopoietic stem cell transplantation (HSCT), both allogeneic and autologous, has become one of the hottest topics in clinical immunology. One of the main autoimmune diseases in which HSCT…

2010 May; 6(5) : 247-55. Epub 2010 Apr 20. Stem cell transplantation in multiple sclerosis: current status and future prospects. Martino G, Franklin RJ, Van Evercooren AB, Kerr DA; Stem Cells in Multiple Sclerosis (STEMS) Consensus Group. Institute of Experimental Neurology-DIBIT 2, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy. martino.gianvito@hsr.it Abstract This article…

2010 Apr;16(4):503-10 The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, Scolding N, Slavin S, Le Blanc K, Uccelli A Abstract Current therapies for multiple sclerosis effectively reduce inflammation, but…